ASS-1 negative AML blasts were particularly sensitive to ADI-PEG treatment when tested in vitro, and when administered in combination with cytarabine, they reduced AML burden in murine models of disease (105). The gene discussed is ASS1; the disease is acute myeloid leukemia.